Urology – Page 3

Durvalumab Combined with BCG for High-Risk, BCG-Naive Non-Muscle-Invasive Bladder Cancer: Final Phase 3 Trial Results from POTOMAC Study

By MedXY 11/11/2025

One year of durvalumab combined with BCG induction and maintenance significantly improved disease-free survival in patients with high-risk, BCG-naive non-muscle-invasive bladder cancer compared to BCG therapy alone, with a manageable safety profile.

news Oncology Urology

Lutetium-177 PSMA Radioligand Therapy Improves Disease Control but Not Yet Overall Survival in mCRPC: A Critical Appraisal of a Six‑RCT Meta-Analysis

By MedXY 11/06/2025

A meta-analysis of six randomized trials shows [177Lu]Lu‑PSMA significantly increases PSA and objective responses and reduces risk of radiographic progression, with no significant increase in high‑grade toxicity and no clear overall survival benefit to date.

news Oncology Urology

[Lutetium-177]Lu-PSMA-617 Delays Quality-of-Life Decline, Pain Progression, and Symptomatic Skeletal Events in PSMA-Positive mCRPC: In-depth PSMAfore Analysis

By MedXY 11/05/2025

PSMAfore shows that [177Lu]Lu-PSMA-617 given to taxane‑naive, PSMA-positive mCRPC patients delays worsening of health-related quality of life, pain, and first symptomatic skeletal events versus switching AR pathway inhibitors.

news Oncology Urology

Baseline PSMA Total Tumor Volume Predicts Who Benefits from Adding 177Lu‑PSMA‑617 to Enzalutamide in First‑line mCRPC

By MedXY 11/05/2025

In ENZA‑p (ANZUP1901) substudy, baseline PSMA PET total tumour volume (PSMA‑TTV) was strongly prognostic for overall survival and predicted greater OS benefit from adding 177Lu‑PSMA‑617 to enzalutamide; PSMA SUVmean was not predictive.

news Oncology Urology

Combining α and β Radiopharmaceuticals in mCRPC: Interim AlphaBet Results Show Feasible Safety and Promising PSA Activity for 177Lu‑PSMA‑I&T plus 223Ra

By MedXY 11/05/2025

Interim data from the AlphaBet phase 1/2 trial show that combined 177Lu‑PSMA‑I&T and radium‑223 is feasible, with no dose‑limiting toxicities, a recommended radium‑223 dose of 55.0 kBq/kg, and a PSA50 rate of 55% (95% CI 36–72). Hematologic grade ≥3 adverse events were uncommon.

news Oncology Urology

Talazoparib plus Enzalutamide Significantly Prolongs Survival in mCRPC: Final TALAPRO-2 Results Confirm Greatest Benefit in BRCA‑Altered Disease

By MedXY 11/05/2025

Final TALAPRO-2 data show that adding talazoparib to enzalutamide improves overall survival and rPFS in metastatic castration‑resistant prostate cancer, with the largest benefit in BRCA1/2‑altered tumors; hematologic toxicity is common but manageable.

news Oncology Urology

Abemaciclib plus Abiraterone Fails to Improve rPFS in mCRPC: Lessons from the CYCLONE 2 Phase 3 Trial

By MedXY 11/05/2025

The phase 3 CYCLONE 2 trial found that adding the CDK4/6 inhibitor abemaciclib to abiraterone did not significantly prolong radiographic progression‑free survival in men with metastatic castration‑resistant prostate cancer and increased toxicity, including treatment‑related interstitial lung disease.

news Oncology Urology

European Prostate Cancer Screening After 23 Years: Sustained Mortality Reduction and Improved Harm-Benefit Profile

By MedXY 10/31/2025

The 23-year follow-up of the ERSPC confirms that PSA screening reduces prostate cancer mortality by 13%, with an improved harm-benefit ratio, supporting risk-based screening strategies to optimize outcomes.

news Oncology Urology

Evolving Treatment Patterns and Survival Outcomes in Veterans With De Novo Metastatic Hormone-Sensitive Prostate Cancer

By MedXY 10/30/2025

A retrospective study in US veterans reveals increased use of combination therapies for metastatic hormone-sensitive prostate cancer (mHSPC), showing improved survival over ADT alone. ARPIs and docetaxel demonstrate comparable overall survival, with ARPIs providing longer progression-free survival.

news Oncology Urology

Age-Dependent Benefits of Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer: A Comprehensive Meta-Analysis

By MedXY 10/30/2025

This meta-analysis reveals that systemic treatment intensification improves overall survival in metastatic hormone-sensitive prostate cancer, with greater benefits in younger men and nuanced effects in older men, especially based on disease volume.

news Oncology Radiology Urology

Visual Whole-Body Tumor-Burden Classification via PSMA PET/CT: Advancing Prognostic Stratification and Therapy Response Prediction in Metastatic Hormone-Sensitive Prostate Cancer

By MedXY 10/30/2025

A novel PSMA PET/CT-based tumor-burden classification effectively stratifies metastatic hormone-sensitive prostate cancer patients, predicting response and prognosis with androgen receptor signaling inhibitors, especially second-generation treatments.

news Oncology Urology

Optimizing Therapy for Older Patients with Metastatic Hormone-Sensitive Prostate Cancer: Insights from a Network Meta-Analysis of Doublet versus Triplet Regimens

By MedXY 10/30/2025

This network meta-analysis reveals that triplet therapy with darolutamide, ADT, and docetaxel offers the greatest overall survival benefit for older patients with metastatic hormone-sensitive prostate cancer, highlighting the need to balance efficacy and toxicity.

news Oncology Urology

Age-Related Impact of Treatment Intensification on Survival in Metastatic Hormone-Sensitive Prostate Cancer

By MedXY 10/30/2025

Systemic treatment intensification improves overall survival in metastatic hormone-sensitive prostate cancer, but its benefit varies by age and disease volume. Older men, particularly with low-volume disease, may have limited survival gains from intensified therapy.

news Oncology Urology

Rethinking Gleason Grade Group 1 Prostate Cancer: Insights from a Large-Scale Cohort Study

By MedXY 10/27/2025

This study highlights the heterogeneity of GG1 prostate cancer and its implications for classification and management strategies.

news Oncology Urology

Enhancing Survival in Biochemically Recurrent Prostate Cancer: The Promising Role of Enzalutamide

By MedXY 10/25/2025

This review highlights the recent findings from the EMBARK trial demonstrating improved overall survival with enzalutamide combined with leuprolide in high-risk recurrent prostate cancer.

Oncology Pathology & Lab Medicine Urology

ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer: Translating Precision Oncology into Improved Outcomes

By MedXY 10/25/2025

This review synthesizes pivotal evidence from the IMvigor011 trial demonstrating that ctDNA-guided adjuvant atezolizumab significantly improves disease-free and overall survival in muscle-invasive bladder cancer, enabling risk-adapted immunotherapy after cystectomy.

news Oncology Urology

Long-Term Efficacy and Safety of Belzutifan in von Hippel-Lindau Disease-Associated Renal Cell Carcinoma: Insights from the 50-Month LITESPARK-004 Phase 2 Study

By MedXY 10/25/2025

Belzutifan demonstrates sustained tumor response and manageable safety over 50 months in patients with von Hippel-Lindau disease-associated renal cell carcinoma, supporting its role as a systemic therapy.

Oncology Urology

Innovative Immunotherapy Combines to Transform Treatment of HER2-Expressing Advanced Urothelial Cancer

By MedXY 10/25/2025

This study demonstrates that disitamab vedotin plus toripalimab significantly improves survival outcomes over chemotherapy in untreated HER2-positive advanced urothelial cancer.

Oncology Urology

Breakthrough ADC-Based Combination Therapy Achieves Over 95% Disease Control in Advanced Urothelial Cancer

By MedXY 10/24/2025

Datroway combined with rilvegostomig demonstrates impressive tumor response and disease control in advanced urothelial carcinoma, heralding a new therapeutic option in first- and second-line settings.

news Urology

Enhancing Postoperative Sexual Readiness in Urogynecologic Surgery: Insights from a Randomized Trial

By MedXY 10/24/2025

A recent trial evaluates the effectiveness of counseling interventions on patient preparedness and sexual outcomes after pelvic surgeries.